EE03528B1 - Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine - Google Patents

Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine

Info

Publication number
EE03528B1
EE03528B1 EE9700175A EE9700175A EE03528B1 EE 03528 B1 EE03528 B1 EE 03528B1 EE 9700175 A EE9700175 A EE 9700175A EE 9700175 A EE9700175 A EE 9700175A EE 03528 B1 EE03528 B1 EE 03528B1
Authority
EE
Estonia
Prior art keywords
preparation
valaciclovir hydrochloride
valaciclovir
hydrochloride
Prior art date
Application number
EE9700175A
Other languages
English (en)
Estonian (et)
Other versions
EE9700175A (et
Inventor
Howard Carter Barry
Muse Partin Jane
Gregory Varlashkin Peter
Augustus Winnike Richard
Bayne Grubb William
Alan Conway Gregory
George Lake Philip
Michael Skinner David
James Whatrup David
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE03528(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Publication of EE9700175A publication Critical patent/EE9700175A/xx
Publication of EE03528B1 publication Critical patent/EE03528B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
EE9700175A 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine EE03528B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (2)

Publication Number Publication Date
EE9700175A EE9700175A (et) 1998-02-16
EE03528B1 true EE03528B1 (et) 2001-10-15

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9700175A EE03528B1 (et) 1995-01-20 1996-01-19 Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine

Country Status (40)

Country Link
US (1) US6107302A (de)
EP (1) EP0804436B1 (de)
JP (1) JP3176633B2 (de)
KR (1) KR100376074B1 (de)
CN (1) CN1049893C (de)
AP (1) AP662A (de)
AR (1) AR002270A1 (de)
AT (1) ATE302777T1 (de)
AU (1) AU702794B2 (de)
BG (1) BG63393B1 (de)
BR (1) BR9606768A (de)
CA (1) CA2210799C (de)
CY (1) CY2531B1 (de)
CZ (1) CZ297065B6 (de)
DE (1) DE69635106T2 (de)
DK (1) DK0804436T3 (de)
EA (1) EA000364B1 (de)
EE (1) EE03528B1 (de)
ES (1) ES2248806T3 (de)
FI (1) FI973063A (de)
GB (1) GB9501178D0 (de)
GE (1) GEP20001940B (de)
HR (1) HRP960024B1 (de)
HU (1) HU222993B1 (de)
IL (1) IL116831A (de)
IN (1) IN182468B (de)
IS (1) IS2268B (de)
NO (1) NO315558B1 (de)
NZ (1) NZ298851A (de)
OA (1) OA10499A (de)
PL (1) PL182175B1 (de)
RO (1) RO118693B1 (de)
RS (1) RS49518B (de)
SI (1) SI0804436T1 (de)
SK (1) SK285329B6 (de)
TR (1) TR199700656T1 (de)
UA (1) UA46001C2 (de)
UY (1) UY25779A1 (de)
WO (1) WO1996022291A1 (de)
ZA (1) ZA96449B (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
DK1368349T3 (da) * 2001-02-24 2007-05-21 Boehringer Ingelheim Pharma Xanthinderivater, deres fremstilling og deres anvendelse som lægemidler
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
EP1453834A1 (de) * 2001-11-05 2004-09-08 Glaxo Group Limited Wasserfreie kristallform von valaciclovir-hydrochlorid
IL161969A0 (en) * 2001-11-14 2005-11-20 Teva Pharma Synthesis and purification of valacyclovir
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
CA2548608A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1891071B1 (de) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (de) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir Polymorphe und Verfahren zu deren Herstellung
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN107235980A (zh) 2006-05-04 2017-10-10 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
MX2010001821A (es) * 2007-08-17 2010-03-10 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US8513264B2 (en) 2008-09-10 2013-08-20 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
UY32048A (es) * 2009-01-08 2010-03-26 Boehringer Ingelheim Int Derivados sustituido de 1-(sustituido)-3-metil-7-(sustituido)-8-(3-(R)-amino-piperidin-1-il)cantina y derivados sustituidos de 1-(sustituido) - 4 - fluoropirrolidin- 2 - carbonitrilo y sus sales famacéuticamente aceptables como inhibidores de DPP-4 y aplicaciones.
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
BR112012028136A2 (pt) 2010-05-05 2016-08-09 Boehringer Ingelheim Int terapia de combinaçao
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
ES2953123T3 (es) 2010-06-24 2023-11-08 Boehringer Ingelheim Int Terapia para la diabetes
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
EP2852592A4 (de) * 2011-11-25 2015-12-23 Piramal Entpr Ltd Verfahren zur herstellung von valacyclovir-hydrochlorid
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
EP0702682B1 (de) * 1993-06-10 2001-03-14 Rolabo Sl Verfahren zur herstellung von aminosäureester von nukleosid analogen
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
AP9701058A0 (en) 1997-10-31
AU4453996A (en) 1996-08-07
HUP9801836A3 (en) 1999-06-28
AU702794B2 (en) 1999-03-04
NO973326D0 (no) 1997-07-18
OA10499A (en) 2002-04-10
DE69635106T2 (de) 2006-06-08
WO1996022291A1 (en) 1996-07-25
UA46001C2 (uk) 2002-05-15
US6107302A (en) 2000-08-22
RO118693B1 (ro) 2003-09-30
EA199700124A1 (ru) 1997-12-30
SK96597A3 (en) 1998-02-04
CN1179159A (zh) 1998-04-15
EP0804436A1 (de) 1997-11-05
CY2531B1 (en) 2006-04-12
CZ229497A3 (en) 1997-12-17
NZ298851A (en) 1999-01-28
NO973326L (no) 1997-09-16
PL182175B1 (pl) 2001-11-30
YU3396A (sh) 1998-12-23
DK0804436T3 (da) 2005-12-27
IL116831A0 (en) 1996-05-14
IL116831A (en) 1998-10-30
JP3176633B2 (ja) 2001-06-18
EA000364B1 (ru) 1999-06-24
BG101833A (en) 1998-04-30
JPH11503718A (ja) 1999-03-30
SI0804436T1 (sl) 2006-02-28
HU222993B1 (hu) 2004-01-28
CZ297065B6 (cs) 2006-08-16
TR199700656T1 (xx) 1998-03-21
CA2210799C (en) 2008-06-10
FI973063A (fi) 1997-09-18
DE69635106D1 (de) 2005-09-29
BR9606768A (pt) 1997-12-30
AR002270A1 (es) 1998-03-11
SK285329B6 (sk) 2006-11-03
IS2268B (is) 2007-07-15
HRP960024A2 (en) 1997-10-31
ATE302777T1 (de) 2005-09-15
NO315558B1 (no) 2003-09-22
ZA96449B (en) 1996-08-07
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
EE9700175A (et) 1998-02-16
AP662A (en) 1998-08-19
HRP960024B1 (en) 2005-08-31
IN182468B (de) 1999-04-17
IS4527A (is) 1997-07-15
ES2248806T3 (es) 2006-03-16
PL321326A1 (en) 1997-12-08
UY25779A1 (es) 2000-08-21
MX9705462A (es) 1997-10-31
FI973063A0 (fi) 1997-07-18
CA2210799A1 (en) 1996-07-25
KR19980701525A (ko) 1998-05-15
RS49518B (sr) 2006-10-27
GB9501178D0 (en) 1995-03-08
KR100376074B1 (ko) 2003-06-02
GEP20001940B (en) 2000-02-05
EP0804436B1 (de) 2005-08-24
HUP9801836A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
EE03528B1 (et) Valatsükloviirvesinikkloriid, selle valmistamismeetod ja kasutamine
EE03338B1 (et) Tromboosivastane ravim, selle valmistamise protsess ja kasutamine
CY2013003I2 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
EE03482B1 (et) Kinasoliiniderivaadid, nende valmistamismeetod ja kasutamine
DE59510981D1 (de) Bohrfutter
DE59510926D1 (de) Bohrfutter
DE69612854D1 (de) Spannfutter
DE19581725T1 (de) Spannfutter
EE03568B1 (et) Bensimidasooli derivaadid, nende valmistamismeetod ja kasutamine
FI980023A (fi) Sienilääke, siihen soveltuva yhdiste, menetelmä niiden valmistamiseksi ja menetelmä niiden käyttämiseksi
DE69528980D1 (de) Bohrfutter
BR9611020A (pt) Conjunto de dispensador de dois tubos adaptador para uso no mesmo e processo para produzir um dispensador de dois tubos
DE69514175D1 (de) Spannfutter
DE69605743D1 (de) Druckverfahren
DE69520558D1 (de) Halogenierungsverfahren
BR9501980A (pt) Copolimeros,processo para sua preparação
ATE232198T1 (de) Aminierungsverfahren
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
DE69603161D1 (de) Druckverfahren
EE03351B1 (et) Meetod lerkanidipiinhüdrokloriidi valmistamiseks
DK0726265T3 (da) 10-Aminoaliphatyl-dibenz[b,f]oxepiner med antineurodegenerativ virkning
DK0727416T3 (da) Substituerede benzensulfonylurinstoffer og -thiourinstoffer, og fremgangsmåde til deres fremstilling, deres anvendelse som
FI941914A (fi) 2-amino-4-kinoliinidihydropyridiinejä, menetelmiä niiden valmistamiseksi ja niiden käyttö
NO972239D0 (no) Ny replikasjonsprosess
BR9506969A (pt) Cames múltiplos

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20110119